Nationwide Trends in COVID-19 Cases and SARS-CoV-2 RNA Wastewater Concentrations in the United States.

Autor:	Duvallet C; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Wu F; Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.; MIT Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States., McElroy KA; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Imakaev M; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Endo N; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Xiao A; Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.; MIT Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States., Zhang J; Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.; MIT Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States., Floyd-O'Sullivan R; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Powell MM; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Mendola S; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Wilson ST; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Cruz F; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Melman T; Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Sathyanarayana CL; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Olesen SW; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Erickson TB; Department of Emergency Medicine, Harvard Medical School, Boston, Massachusetts 02115, United States.; Division of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.; Harvard Humanitarian Initiative, Cambridge, Massachusetts 02138, United States., Ghaeli N; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States., Chai P; Division of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.; The Fenway Institute, Boston, Massachusetts 02215, United States.; The Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139-4307, United States., Alm EJ; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States.; Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.; MIT Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, United States.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States., Matus M; Biobot Analytics, Inc., Cambridge, Massachusetts 02139, United States.
Jazyk:	angličtina
Zdroj:	ACS ES&T water [ACS ES T Water] 2022 Nov 11; Vol. 2 (11), pp. 1899-1909. Date of Electronic Publication: 2022 May 03.
DOI:	10.1021/acsestwater.1c00434
Abstrakt:	Wastewater-based epidemiology has emerged as a promising technology for population-level surveillance of COVID-19. In this study, we present results of a large nationwide SARS-CoV-2 wastewater monitoring system in the United States. We profile 55 locations with at least six months of sampling from April 2020 to May 2021. These locations represent more than 12 million individuals across 19 states. Samples were collected approximately weekly by wastewater treatment utilities as part of a regular wastewater surveillance service and analyzed for SARS-CoV-2 RNA concentrations. SARS-CoV-2 RNA concentrations were normalized to pepper mild mottle virus, an indicator of fecal matter in wastewater. We show that wastewater data reflect temporal and geographic trends in clinical COVID-19 cases and investigate the impact of normalization on correlations with case data within and across locations. We also provide key lessons learned from our broad-scale implementation of wastewater-based epidemiology, which can be used to inform wastewater-based epidemiology approaches for future emerging diseases. This work demonstrates that wastewater surveillance is a feasible approach for nationwide population-level monitoring of COVID-19 disease. With an evolving epidemic and effective vaccines against SARS-CoV-2, wastewater-based epidemiology can serve as a passive surveillance approach for detecting changing dynamics or resurgences of the virus. Competing Interests: The authors declare the following competing financial interest(s): C.D., K.A.M., N.E., M.I., R.F.-O., M.M.P., S.M., S.T.W., F.C., T.M., C.L.S., and S.W.O. are current or former employees of Biobot Analytics, Inc. E.J.A. is scientific advisor to Biobot Analytics, Inc. (© 2022 The Authors. Published by American Chemical Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu